 EMERYVILLE, Calif., July 15, 2021 GLOBE NEWSWIRE -- Gritstone bio, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the Compensation Committee of the companys Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 77,800 shares of its common stock with an exercise price of 8.77, which is equal to the closing price of Gritstones common stock on July 12, 2021, the grant date of the awards. Additionally, the companys recently appointed chief financial officer, Celia Economides, was granted nonqualified stock options to purchase 215,000 shares of its common stock with an exercise price of 9.76 based on the closing price on June 23, 2021, the grant date of the award. These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635c4. 